Search

Pipendoxifene

ER modulator, ERA-923(Pipendoxifene) is a estrogen receptor modulator being evaluated for the treatment of breast cancer.

Alpelisib

Alpelisib was granted FDA approval on 24 May 2019. … [L6652] In April 2022, the FDA granted the use of alpelisib in the treatment of PIK3CA-Related Overgrowth Spectrum (PROS) in adults and children who require systemic therapy.[L41384]

Sirolimus

[A242412] In May 2015, the FDA approved sirolimus for the treatment of patients with lymphangioleiomyomatosis. … [A1320] Sirolimus was first approved by the FDA in 1999 for the prophylaxis of organ rejection in patients aged 13 years and older receiving renal transplants.

Bacitracin

[A181952] Bacitracin was granted FDA approval on 29 July 1948.[A181997,L7748]

Bedaquiline

[A261856,A261861] It is the first drug that was approved in the last 40 years by the FDA for TB unresponsive to current treatments on the market. … [A261861] Bedaquiline was approved by the FDA on December 28, 2012, to treat pulmonary MDR-TB, following favorable results in multiple pre-clinical and clinical studies.

Gilteritinib

[A40044] Gilteritinib was developed by Astellas Pharma and FDA approved on November 28, 2018.

Inavolisib

Inavolisib is an inhibitor of PI3Kα that was approved by the FDA in October 2024 for the treatment of certain patients with advanced breast cancers.

Oxilofrine

Oxilofrine is used in combination with DB11609 as an antitussive. It is currently marketed in Canada by Valeant under the tradename Cophylac.

Sodium borate

Rilpivirine

[A31331] Rilpivirine was developed by Tilbotec, Inc. and FDA approved on May 20, 2011. … [L1031] Rilpivirine in combination with [cabotegravir] was granted FDA approval on 21 January 2021.